Skip to main content

Liquidia Corp

corporate_fare Company Profile

Liquidia Corp

LQDA·NASDAQ·Life Sciences·CIK 0001819576

Liquidia Corporation is a biopharmaceutical company focused on respiratory and vascular diseases, including pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company operates through its wholly owned subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Liquidia generates revenue from the sale of YUTREPIA (treprostinil) inhalation powder. Additionally, under a promotion agreement with Sandoz Inc. dated August 1, 2018, Liquidia shares profit from the sale of Sandoz's generic treprostinil injection (Treprostinil Injection) in the United States. YUTREPIA is an inhaled dry powder formulation of treprostinil, developed using Liquidia's proprietary PRINT technology. This technology aims to improve treprostinil's therapeutic profile through enhanced deep lung delivery, a low-effort dry-powder inhaler, and the ability to achieve higher dose levels than other marketed inhaled treprostinil therapies. YUTREPIA was approved by the U.S. Food and Drug Administration (FDA) in May 2025 for treating PAH and PH-ILD, with commercialization beginning in June 2025. Liquidia has exclusive rights to commercial activities for Treprostinil Injection in the United States and collaborates with Sandoz on its commercial strategy. Sandoz holds the Abbreviated New Drug Application (ANDA) for Treprostinil Injection and retains all other rights to the product. The company also conducts research, development, and manufacturing of new products. An example is L606, an investigational liposomal formulation of treprostinil, licensed from Pharmosa Biopharm Inc. Liquidia employs a commercial field force targeting healthcare providers and stakeholders involved in treating PAH and PH-ILD in the United States.

Liquidia Corp (NASDAQ:LQDA) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 35 items for LQDA at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Director Paul B Manning Files to Sell $11.1M in Liquidia Stock Amidst Broader Insider Distribution
  • Director-Affiliated Entity Files to Sell $13M in Liquidia Stock
  • Director Sells $1.77M in Stock After Option Exercise
  • Director Ramandeep Singh Files to Sell $1.77 Million in Liquidia Corp Stock
  • Insider-affiliated entity files to sell $6.38M in Liquidia Corp stock

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$158.32M
Net Income
-$68.92M
Diluted EPS
-$0.80
Op. Cash Flow
-$35.69M
Free Cash Flow
-$40.02M
Operating Income
-$51.38M
Cash & Equivalents
$190.68M
Debt / Equity
0.00×
Net Margin
-43.5%
Shares Outstanding
87.2M sh
Source: 10-K · filed 2026-03-05 · accession 0001104659-26-023804
$54.75 +0.59% today
52-week range · as of 2026-11-10 $22.31 – $93.61
Market cap
$4.9B
Volume
1.7M (0.5× avg)
3-mo avg 3.8M
Live data · 2026-11-21 23:41 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed LQDA - Filings & News (Page 2)

LQDA
Jun 04, 2026, 6:38 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $63.00
Real-time Price: $54.75 info
Change: -$8.25 (-13%) info
Market Cap: $4.904B info
LQDA
Jun 04, 2026, 5:24 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $62.50
Real-time Price: $54.75 info
Change: -$7.75 (-12%) info
Market Cap: $4.904B info
LQDA
May 26, 2026, 6:17 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $60.63
Real-time Price: $54.75 info
Change: -$5.88 (-10%) info
Market Cap: $4.904B info
LQDA
May 21, 2026, 5:12 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $61.70
Real-time Price: $54.75 info
Change: -$6.95 (-11%) info
Market Cap: $4.904B info
LQDA
May 20, 2026, 4:37 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $61.77
Real-time Price: $54.75 info
Change: -$7.02 (-11%) info
Market Cap: $4.904B info
LQDA
May 11, 2026, 5:52 PM EDT
Filing Type: 144
Importance Score:
8
Price at Filing: $52.56
Real-time Price: $54.75 info
Change: +$2.19 (+4%) info
Market Cap: $4.904B info
LQDA
May 11, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $44.98
Real-time Price: $54.75 info
Change: +$9.77 (+22%) info
Market Cap: $4.904B info
LQDA
May 11, 2026, 6:45 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $43.50
Real-time Price: $54.75 info
Change: +$11.25 (+26%) info
Market Cap: $4.904B info
LQDA
May 11, 2026, 6:30 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $43.74
Real-time Price: $54.75 info
Change: +$11.01 (+25%) info
Market Cap: $4.904B info
LQDA
Apr 09, 2026, 4:21 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $40.32
Real-time Price: $54.75 info
Change: +$14.43 (+36%) info
Market Cap: $4.904B info
LQDA
Mar 17, 2026, 4:30 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $36.86
Real-time Price: $54.75 info
Change: +$17.89 (+49%) info
Market Cap: $4.904B info
LQDA
Mar 05, 2026, 7:01 AM EST
Filing Type: 10-K
Importance Score:
8
Price at Filing: $35.89
Real-time Price: $54.75 info
Change: +$18.86 (+53%) info
Market Cap: $4.904B info
LQDA
Mar 05, 2026, 6:45 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.50
Real-time Price: $54.75 info
Change: +$23.25 (+74%) info
Market Cap: $4.904B info
LQDA
Mar 05, 2026, 6:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $32.75
Real-time Price: $54.75 info
Change: +$22.00 (+67%) info
Market Cap: $4.904B info
LQDA
Jan 09, 2026, 6:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $31.85
Real-time Price: $54.75 info
Change: +$22.90 (+72%) info
Market Cap: $4.904B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets